NCT03646591 is a clinical trial of Chemotherapy in Chemotherapy Effect, sponsored by Ruijin Hospital.

Who is sponsoring NCT03646591?

NCT03646591 is sponsored by Ruijin Hospital.

What drugs are being tested in NCT03646591?

Interventions in NCT03646591: Chemotherapy.

What condition does NCT03646591 study?

NCT03646591 studies Chemotherapy Effect.

Is NCT03646591 still recruiting?

NCT03646591 is currently completed. Last updated 13 November 2020.

Last reviewed 2020-11-13 · How we verify

NCT03646591

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Feasibility and Safety of Neoadjuvant Chemotherapy (FLOT ) for Gastric Cancer Patients in China

Completed Last updated 13 November 2020

What this trial tests

trial testing Chemotherapy in Chemotherapy Effect in 10 participants. Completed in 20 August 2018.

Timeline

15 November 2017

Primary endpoint
20 August 2018

20 August 2018

Quick facts

Lead sponsor	Ruijin Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	10
Start date	15 November 2017
Primary completion	20 August 2018
Estimated completion	20 August 2018
Sites	1 location across China

Drugs / interventions tested

Chemotherapy (chemotherapy) — full drug profile →

Conditions studied

Chemotherapy Effect — all drugs for Chemotherapy Effect →

Sponsor

Ruijin Hospital

Who can join

Adults 18 to 80, any sex, with Chemotherapy Effect. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Neoadjuvant chemotherapy for advanced-stage gastric cancer is justified by various studies, however, there was not any large scale randomized controlled trial (RCT) to support it until German oncologist introduced a novel regimen(FLOT regimen) in 2017. Investigator assessed the FLOT regimen for safety and feasibility in Chinese gastric cancer patients.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Feasibility and Safety of Perioperative Chemotherapy With Fluorouracil Plus Leucovorin, Oxaliplatin, and Docetaxel for Locally Advanced Gastric Cancer Patients in China.
Sah BK, Xu W, Zhang B, Zhang H, et al · · 2020 · cited 7× · PMID 33537232 · DOI 10.3389/fonc.2020.567529
Dragon III- Phase 1: Feasibility and safety of neoadjuvant chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel (FLOT) for locally-advanced gastric cancer patients in China
Sah BK, Xu W, Zhang B, Zhang H, et al · · 2020 · DOI 10.1101/2020.05.22.20110668

Verify or expand the search:

Other trials of Chemotherapy

Trials testing the same drug.

NCT07391774 — Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribocic · Phase 3 · not yet recruiting
NCT07476287 — Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult · Phase 2 · recruiting
NCT07392892 — A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer · Phase 2, PHASE3 · recruiting
NCT07288034 — Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatmen · Phase 2 · recruiting
NCT07078604 — A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negati · Phase 2 · recruiting

Other recruiting trials for Chemotherapy Effect

Currently open trials in the same condition.

NCT06525402 — Effect of Sodium Bicarbonate, Saline and Black Mulberry Syrup on Degree of Oral Mucositis in Children Receiving Chemothe · NA · recruiting
NCT06510010 — Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer · Phase 2 · recruiting
NCT06944587 — A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer · recruiting
NCT05864274 — Improve Cancer-related Cognitive Impairment · NA · recruiting
NCT06863623 — The Effect of Immersive Virtual Reality and Relaxing Videos on Lung Cancer Patients · NA · recruiting

Other Ruijin Hospital trials

Trials by the same sponsor.

NCT07589361 — Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors · not yet recruiting
NCT07449507 — Partially Hydrolyzed Whey Protein Formula for Infants With Mild Allergy · NA · not yet recruiting
NCT07496385 — Clinical Study on the Efficacy of Subglottic Suction in Mechanically Ventilated Patients Guided by Bedside Ultrasound · NA · not yet recruiting
NCT07511114 — A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyp · Phase 3 · not yet recruiting
NCT07514169 — The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03646591 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ruijin Hospital
Last refreshed: 13 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03646591.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing